The current literature on the gut microbiome in type 1

The gap

Evidence profile

Sourced from the future work and limitations and stated research gap of the source papers, classified as general, spanning 3 journals.

Supporting evidence — 3 representative gaps

• Microbiome-orchestrated cross-organ immunity in autoimmunity: from metabolites to therapeutic targets (2026) · Frontiers in Immunology · doi

  Accumulating data support a central role for the microbiome and its metabolites in autoimmunity, yet the gaps identified below map directly onto the preceding framework. Metabolite-centered mechanisms require stronger causal validation, cross-organ models require better tissue sampling and trajectory analysis, and therapeutic translation requires safety, regulatory and biomarker standards. Current evidence remains dominated by cross-sectional association studies with heterogeneous cohorts, variable sampling protocols and incomplete control of diet, medication and comor- bidities. A coordinated roadmap should integrate longitudinal human cohorts, mechanistic experimental systems and rigorous computational inference to test whether defined microbiome-me- tabolite modules can alter autoimmune trajectories rather than merely correlate with them. 8.1 Causality vs association Most microbiome-autoimmunity studies still describe compo- sitional differences between patients and controls, which are vul- nerable to confounding and reverse causation (105). Few autoimmune cohorts currently meet the ideal standard of dense longitudinal sampling before disease onset, during flare, remission and treatment transition with harmonized diet, medication and multi-organ immune readouts. Mendelian randomization analyses support putative causal links between specific gut microbes and autoimmune diseases such as rheumatoid arthritis, multiple scle- rosis and systemic lupus erythematosus, but effect sizes are modest and instruments are often weak (8, 106). Horizontal pleiotropy, population stratification and taxonomic imprecision further limit interpretation. Controlled dietary, probiotic or metabolite-interven- tion trials with prespecified immune endpoints provide a comple- mentary path beyond correlation (88, 107). A priority is to combine m i c r o b i a l o r m e t a b o l i t e p e r t u r b a t i o n w i t h d e e p immunophenotyping and target-organ readouts to test whether manipulating defined microbial functions can alter flares, progres- sion or treatment responses in a tissue-specific manner (76, 108). 8.2 Inter individual variability and context dependence Marked inter individual variability in microbiome composition and function complicates the definition of disease associated signatures and therapeutic targets. Large population studies dem- onstrate that geography, diet, lifestyle, antibiotics, and other med- ications explain a substantial fraction of microbiome variance, often exceeding the contribution of single host genetic loci (109). Even among “healthy” individuals, there is a wide continuum of taxo- nomic and metabolic configurations, which challenges the use of simple dysbiosis labels and undermines the notion of a single healthy reference state (110). Autoimmune patients add further layers of heterogeneity, including age, sex, disease duration, organ involvement, background immunosuppression, and comorbid met- abolic or infectious conditions. These contextual factors modulate metabolite production, barrier function, and immune tone, so that the same microbial pathway may be protective in one setting and pathogenic in another. Future work should adopt stratified designs that pre specify clinically relevant subgroups, use harmonized sampling and analytical pipelines, and explicitly model interactions between microbiome features, host variables, and treatments, rather than adjusting them away as mere confounders (108).

  generalfuture workevidence 5/5
  Keywords: microbiome organ sampling autoimmune metabolite cohorts diet disease immune support autoimmunity require causal cross tissue
• Gut microbiota alters cardiac metabolism and immune system composition in viral myocarditis mice (2026) · Frontiers in Microbiology · doi

  Our present study has some limitations. First, our experiment was based on a mouse model of VMC, and these findings need to be further supported by relevant clinical trials. Furthermore, increasing the sample size in future studies could help reduce the biological variability observed in the VMC group. Second, regarding biomarker microbiota such as Streptococcus, we observed alterations in metabolic profiles and immunity responses following FMT/ABX treatment; however, we did not explore the downstream metabolic or immune pathways and mechanisms, or provide causal evidence. Future study is needed, such as focusing on how specific changes in the microbiota directly cause alterations in specific metabolites. And how do these metabolites act on immune cells? In addition, we only observed the acute stage of myo- carditis and lacked late-stage myocarditis, such as dilated cardiomyopa- thy (DCM). In the near future, we plan to conduct studies on chronic myocarditis and DCM to further deepen our knowledge of the mecha- nisms by which the gut microbiota affects VMC.

  generallimitationsevidence 5/5
  Keywords: future observed microbiota further alterations metabolic immune specific metabolites stage myocarditis present limitations first experiment
• Gut microbiota and the early prevention window in type 1 diabetes and latent autoimmune diabetes in adults: a state-of-the-art narrative review on diet and metabolites (2026) · Frontiers in Endocrinology · doi

  The current literature on the gut microbiome in type 1 diabetes and latent autoimmune diabetes in adults is highly heterogeneous, with varying study designs, populations, and microbiome assessment platforms. There is a need for more prospective, mechanistic, and translational research to understand the role of the gut microbiome in autoimmune diabetes. The authors identify stage- and age-specific windows of susceptibility as a key area for future research, with potential applications for developing low-risk, mechanistically plausible dietary and microbiome-modulating strategies.

  generalstated research gapevidence 5/5
  Keywords: current literature gut microbiome type diabetes latent autoimmune

Questions about this gap